Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Aslan Pharmaceuticals appoints Kenneth Kobayashi, MD, as Chief Medical Officer » 05:33
08/03/20
08/03
05:33
08/03/20
05:33
ASLN

Aslan Pharmaceuticals

$1.54 /

-0.065 (-4.06%)

ASLAN Pharmaceuticals…

ASLAN Pharmaceuticals (ASLN) announced that Dr. Kenneth Kobayashi has been appointed Chief Medical Officer. Dr Kobayashi will be based in California and will be responsible for the global clinical development of ASLAN's pipeline, including the lead program, ASLAN004, an antibody that blocks the IL-13 receptor, which is being developed for atopic dermatitis. He most recently served as Senior Medical Director at Dermira, a subsidiary of Eli Lilly (LLY).

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.54 /

-0.065 (-4.06%)

ASLN Aslan Pharmaceuticals
$1.54 /

-0.065 (-4.06%)

04/13/20 Piper Sandler
Aslan interim data for ASLN004 study still expected in 2020, says Piper Sandler
03/18/20 Piper Sandler
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler
12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
ASLN Aslan Pharmaceuticals
$1.54 /

-0.065 (-4.06%)

  • 04
    Dec
Hot Stocks
Aslan Pharmaceuticals moves primary listing to Nasdaq » 06:10
07/17/20
07/17
06:10
07/17/20
06:10
ASLN

Aslan Pharmaceuticals

$1.86 /

+0.16 (+9.41%)

Aslan Pharmaceuticals…

Aslan Pharmaceuticals announced further progress towards a primary listing on the Nasdaq Global Market and receipt of a Notice of Delisting from the Taipei Exchange, an expected step in the TPEx delisting process. The company will retain its listing of American Depositary Shares on Nasdaq in the United States and existing holders of ADS do not need to take any action as a result of this announcement. Aslan its ordinary shares to cease trading on TPEx on August 25, and TPEx regulations will cease to apply shortly thereafter. Holders of the company's ordinary shares can apply before September 25, to convert their shares into ADS and it is anticipated that the conversion will be completed before the end of October. Aslan is currently recruiting patients into the second of three dose cohorts of its Phase 1 randomised, double-blind, placebo-controlled multiple ascending dose study of ASLAN004 in moderate to severe atopic dermatitis. Recruitment of patients into the study is expected to restart in August as restrictions put in place by the Singapore government to contain the spread of COVID-19 are gradually lifted. Sites in Australia and the U.S. are also preparing to come online to accelerate recruitment. The company expects to announce interim, unblinded data from the study in the fourth quarter of 2020.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.86 /

+0.16 (+9.41%)

ASLN Aslan Pharmaceuticals
$1.86 /

+0.16 (+9.41%)

04/13/20 Piper Sandler
Aslan interim data for ASLN004 study still expected in 2020, says Piper Sandler
03/18/20 Piper Sandler
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler
12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
ASLN Aslan Pharmaceuticals
$1.86 /

+0.16 (+9.41%)

  • 04
    Dec
Hot Stocks
Aslan Pharmaceuticals expects to complete MAD trial in 1H21 » 08:10
07/13/20
07/13
08:10
07/13/20
08:10
ASLN

Aslan Pharmaceuticals

$1.85 /

-0.05 (-2.63%)

Anticipated upcoming…

Anticipated upcoming milestones for ASLAN004: Interim, unblinded data from the 3 dose cohorts expected in 4Q 2020, and initiation of the expansion cohort. Completion of MAD clinical trial in moderate-to-severe AD patients in 1H 2021. Initiation of Phase 2b study of ASLAN004 for AD in 2021.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.85 /

-0.05 (-2.63%)

ASLN Aslan Pharmaceuticals
$1.85 /

-0.05 (-2.63%)

04/13/20 Piper Sandler
Aslan interim data for ASLN004 study still expected in 2020, says Piper Sandler
03/18/20 Piper Sandler
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler
12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
ASLN Aslan Pharmaceuticals
$1.85 /

-0.05 (-2.63%)

  • 04
    Dec
Hot Stocks
Aslan Pharmaceuticals preparing to file investigational NDA for ASLAN004 » 08:09
07/13/20
07/13
08:09
07/13/20
08:09
ASLN

Aslan Pharmaceuticals

$1.85 /

-0.05 (-2.63%)

Recruitment paused into…

Recruitment paused into randomised, double-blind, placebo-controlled MAD study of ASLAN004 in moderate to severe atopic dermatitis in April 2020 in response to government restrictions in Singapore to contain the spread of COVID-19. To accelerate recruitment, ASLAN has identified several clinical sites in Australia and the US that could join the ongoing MAD study in the third quarter. Clinical trial application submitted and regulatory process underway in Australia to initiate recruitment of patients into the ongoing MAD study. Preparations underway to file Investigational New Drug application to the US Food and Drug Administration later this month.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.85 /

-0.05 (-2.63%)

ASLN Aslan Pharmaceuticals
$1.85 /

-0.05 (-2.63%)

04/13/20 Piper Sandler
Aslan interim data for ASLN004 study still expected in 2020, says Piper Sandler
03/18/20 Piper Sandler
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler
12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
ASLN Aslan Pharmaceuticals
$1.85 /

-0.05 (-2.63%)

  • 04
    Dec
Earnings
Aslan Pharmaceuticals reports Q2 EPS (2c), consensus (7c) » 08:08
07/13/20
07/13
08:08
07/13/20
08:08
ASLN

Aslan Pharmaceuticals

$1.85 /

-0.05 (-2.63%)

Dr Carl Firth, CEO, ASLAN…

Dr Carl Firth, CEO, ASLAN Pharmaceuticals, said: "As COVID-19 restrictions gradually lift in Singapore we expect to resume recruitment into our multiple ascending dose study of ASLAN004 in early August. With the continuing impact of COVID-19 causing some delays in patient recruitment, we plan to share further data from the trial during the fourth quarter of 2020. We have been proactive in preparing to open new study sites in Australia and the US to ensure we can accelerate recruitment, as well as support our planned global Phase 2b study in atopic dermatitis in 2021."

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.85 /

-0.05 (-2.63%)

ASLN Aslan Pharmaceuticals
$1.85 /

-0.05 (-2.63%)

04/13/20 Piper Sandler
Aslan interim data for ASLN004 study still expected in 2020, says Piper Sandler
03/18/20 Piper Sandler
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler
12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
ASLN Aslan Pharmaceuticals
$1.85 /

-0.05 (-2.63%)

  • 04
    Dec
Over a quarter ago
Earnings
Aslan Pharmaceuticals reports Q1 EPS (3c), consensus (9c) » 05:59
05/11/20
05/11
05:59
05/11/20
05:59
ASLN

Aslan Pharmaceuticals

$1.74 /

+0.065 (+3.89%)

Dr Carl Firth, CEO, ASLAN…

Dr Carl Firth, CEO, ASLAN Pharmaceuticals, said: "The COVID-19 pandemic has brought about unprecedented changes and affected many worldwide. We have been putting strategies in place to mitigate risks to our development programs, including opening sites in different geographies where restrictions are easing. We are also taking steps to ensure that we emerge from this situation stronger and ready to initiate our planned phase 2b study of ASLAN004 for atopic dermatitis in 1H 2021, building our US presence as we grow a team there and prepare to file an Investigational New Drug application with the FDA."

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.74 /

+0.065 (+3.89%)

04/13/20 Piper Sandler
Aslan interim data for ASLN004 study still expected in 2020, says Piper Sandler
03/18/20 Piper Sandler
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler
12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
Recommendations
Aslan interim data for ASLN004 study still expected in 2020, says Piper Sandler » 11:03
04/13/20
04/13
11:03
04/13/20
11:03
ASLN

Aslan Pharmaceuticals

$1.34 /

+0.155 (+13.08%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating on Aslan Pharmaceutical shares after the company announced that government imposed restriction due to COVID-19 pandemic has resulted in paused enrollment at clinical sites in Singapore for ASLN004 Phase I multiple-ascending dose study in moderate-to-severe atopic dermatitis. Aslan will resume patient screening once restrictions are lifted, expected to be on May 4, Tenthoff tells investors in a research note. He adds that the previously guided data readout for all three cohorts in Q3 is still expected to occur this year to inform a Phase IIb start in 2021.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.34 /

+0.155 (+13.08%)

03/18/20 Piper Sandler
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler
12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
12/02/19 Piper Sandler
Aslan Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray
Hot Stocks
Aslan intends to resume screening after government restrictions lifted » 05:35
04/13/20
04/13
05:35
04/13/20
05:35
ASLN

Aslan Pharmaceuticals

$1.19 /

+0.135 (+12.86%)

Aslan Pharmaceuticals…

Aslan Pharmaceuticals announced that recruitment of new patients into its randomised, double-blind, placebo-controlled multiple ascending dose, or MAD, study of ASLAN004 in moderate to severe atopic dermatitis has been paused in light of recently imposed government restrictions in Singapore to contain the spread of the coronavirus disease (COVID-19). ASLAN does not currently expect these measures to materially affect the projected timelines for the readout of interim, unblinded data later this year. ASLAN was recruiting patients into the second of three dose cohorts. Clinical studies in Singapore, other than those related to COVID-19, have paused recruitment in line with the recent restrictions on movement of the public to contain the spread of COVID-19. ASLAN intends to resume screening of new patients as soon as these restrictions are lifted, which is currently due to take place on May 4. In parallel, ASLAN has identified several clinical sites in Australia, which could join the study mid-year to accelerate recruitment.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.19 /

+0.135 (+12.86%)

03/18/20 Piper Sandler
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler
12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
12/02/19 Piper Sandler
Aslan Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray
Recommendations
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler » 16:47
03/18/20
03/18
16:47
03/18/20
16:47
ASLN

Aslan Pharmaceuticals

$0.94 /

-0.14 (-12.96%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Aslan Pharmaceuticals to $6 from $8 and keeps an Overweight rating on the shares. Tenthoff said he anticipates interim data of all three cohorts of the Phase I ASLAN004 trial in the third quarter of 2020 and completion in the fourth quarter to inform a Phase IIb start in the first half of 2021. The analyst added that the lowered price target is due to removing ASLAN003 AML value.

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$0.94 /

-0.14 (-12.96%)

12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
12/02/19 Piper Sandler
Aslan Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray
11/14/19 H.C. Wainwright
Aslan Pharmaceuticals price target lowered to $2 from $9 at H.C. Wainwright
Earnings
Aslan Pharmaceuticals reports Q4 EPS (7c), consensus (17c) » 06:07
03/18/20
03/18
06:07
03/18/20
06:07
ASLN

Aslan Pharmaceuticals

$1.08 /

-0.04 (-3.57%)

Dr Carl Firth, CEO, ASLAN…

Dr Carl Firth, CEO, ASLAN Pharmaceuticals, said: "2019 marked a year of change for ASLAN as we focused our development efforts on the highly promising ASLAN004, a fully human monoclonal antibody that binds to the IL-13 receptor alpha1 subunit (IL-13R alpha 1), for the treatment of atopic dermatitis, or AD, and asthma. The data we announced last December from our ongoing multiple ascending dose, or MAD, study in AD was very encouraging, showing early signs of efficacy and a favourable side effect profile, and we believe that ASLAN004 has the potential to be a best-in-disease treatment for AD. The second dose cohort is recruiting well and we plan to wait until the end of cohort 3 to announce additional data, when the full dataset can be unblinded rather than releasing additional blinded data at the end of cohort 2. Our recent fundraising has positioned us well to complete the study and, at the same time, prepare to initiate a Phase 2b study in early 2021 as the next step in our development plan."

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.08 /

-0.04 (-3.57%)

12/10/19 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $5 from $2 at H.C. Wainwright
12/02/19 Piper Sandler
Piper upgrades Aslan to Overweight with $8 target after atopic dermatitis data
12/02/19 Piper Sandler
Aslan Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray
11/14/19 H.C. Wainwright
Aslan Pharmaceuticals price target lowered to $2 from $9 at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.